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Abstract
Poly(ADP-ribose) polymerase-1 (PARP-1) is a nuclear DNA-
binding protein that participates in the regulation of DNA repair
and maintenance of genomic integrity. In addition, PARP-1 has
a role in several models of inflammation disease, where its
absence or inactivation confers protection. The aim of this study
was to analyze the impact of selective PARP-1 suppression in
collagen antibody-induced arthritis. We show that PARP-1
deficiency partially reduces the severity of arthritis, although the
incidence of disease was similar in control and deficient mice.
Decreased clinical scores were accompanied by partial
reduction of histopathological findings. Interestingly,
quantitative real-time PCR and ELISA analysis revealed that the
absence of PARP-1 down-regulated IL-1β and monocyte
chemotactic protein 1 expression in arthritic joints whereas
tumor necrosis factor-α transcription was not impaired. Our
results provide evidence of the contribution of PARP-1 to the
progression of arthritis and identify this protein as a potential
therapeutic target for the treatment of rheumatoid arthritis.
Introduction
Rheumatoid arthritis (RA) is characterized by inflammation,
synovial hyperplasia, pannus formation and progressive
destruction of cartilage and bone [1,2]. In RA, inflammatory
cytokines, chemokines, growth factors and adhesion mole-
cules are produced by leukocytes and resident synoviocytes.
These factors perpetuate chronic inflammation by the recruit-
ment of additional inflammatory cells into the sublining region
that, in turn, lead to continuous production of inflammatory
mediators and enzymes, resulting in destruction of joint struc-
tures [3-8]. The efficacy of treatments with tumor necrosis fac-
tor (TNF) and IL-1 inhibitors strongly support the key role of
inflammatory cytokines in the pathogenesis of RA [9,10] and
points to therapeutic approaches directed toward regulation
of cytokine networks involved in RA.
Poly(ADP-ribose) polymerase (PARP)-1 is a highly conserved
nuclear zinc-finger protein involved in maintenance of genomic
integrity. PARP-1 detects DNA breakage generated by several
genotoxic agents and synthesizes and transfers ADP ribose
units (poly(ADPribosyl)ation activity) into acceptor proteins
involved in the conservation of chromatin structure and DNA
metabolism, modulating in this way DNA repair and cell sur-
vival [11,12]. Studies with PARP-1 deficient mice or with
chemical inhibitors have enlarged the physiological role of this
protein. In these situations, lack of PARP-1 function protects
against several disorders with an inflammatory component,
such as endotoxic shock [13], streptozotocin induced diabe-
tes [14], chronic colitis [15] and uveitis [16]. Two mechanisms
have been proposed to explain the role of PARP-1 in these dis-
eases. One mechanism is related to massive PARP-1 activa-
tion induced by genotoxic injury developed during the
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inflammatory process. In this case, hyperactivated PARP-1
would lead to ATP depletion and cell dysfunction [17]. The
other proposed mechanism is related to a functional link
between PARP-1 and inflammation-related transcription fac-
tors. Several in vivo and in vitro studies have demonstrated the
involvement of PARP-1 in the transcriptional activation of
nuclear factor (NF)κB [13,18,19], but the proposed mecha-
nisms are contradictory. There is evidence for mechanisms
that are both dependent on and independent of auto-
poly(ADP-ribosyl)ation function. In the first case, NFκB would
be blocked by binding to PARP-1 and this union would be dis-
rupted by PARP-1 auto-poly(ADP-ribosyl)ation [18]. In the
second case, PARP-1 would act as a transcriptional co-activa-
tor in the binding of NFκB with its target DNA sequences [19].
Recently, it has also been reported that PARP-1 regulates
other transcription factors implicated in stress/inflammation,
such as AP-1, Oct-1, SP-1, YY-1 and Stat-1 [20,21]. Thus, in
addition to its involvement in genome surveillance, PARP-1
appears to have a key role in inflammatory responses.
Here we report the impact of selective PARP-1 suppression
on the collagen antibody-induced arthritis model (CAIA). This
model, induced by passive immunization of mice with anti-type
II collagen antibodies, allows the study of the effector phase of
arthritis, where PARP-1 might be involved. We have found that
the absence of PARP-1 partially reduced the severity of arthri-
tis, likely by the impairment of IL-1β and monocyte chemotac-
tic protein (MCP)-1 transcription in arthritic tissue. These
results provide support for the contribution of PARP-1 in the
progression of arthritis and open the possibility that specific
inhibitors might become therapeutic tools in RA.
Materials and methods
Mice
Mice lacking PARP-1 (kindly provided by G de Murcia, CNRS,
Strasbourg, France) have been described previously [22]. The
mice used in these experiments were of mixed (C57BL/6 ×
129Sv) background. More than ten different breeding pairs of
parp-1+/o mice were intercrossed to generate parp-1+/+, parp-
1+/o and parp-1o/o mice. Parp-1o/o mice and control matched
littermates (parp-1+/+, parp-1+/o) were analyzed.
Genotypes were assessed by PCR of tail DNA. The mice were
maintained in the mouse facility of the Facultad de Medicina de
Santiago de Compostela. Animal care was in compliance with
Spanish regulations on the protection of animals used for
experimental and other scientific purposes (Real Decreto 223/
1998). The experimental protocols were approved by the Ani-
mal Care and Use Committee of the University of Santiago de
Compostela.
Collagen antibody-induced arthritis (CAIA) and clinical 
scoring
CAIA was induced in 6-week-old male and female mice by
intravenous injection on day 0 of 3 mg/mouse of an arthri-
togenic cocktail of 4 monoclonal anti-type II collagen antibod-
ies (Arthrogen, Chondrex, Redmond, WA, USA) [23]. On day
2, mice were boosted with 50 µg of lipopolysaccharide by
intraperitoneal injection. Arthritis was assessed every other
day by two blinded observers until day 12, using a semi-quan-
titative clinical score ranging from 0 to 4: 0, no swelling; 1,
slight swelling and erythema of the ankle, wrist or digits; 2,
moderate swelling and erythema; 3, severe swelling and ery-
thema; and 4, maximal inflammation with joint rigidity. The max-
imum possible score was 16 per mouse.
Histological analysis
Hind limbs were prepared for histology by dissecting the skin
and muscle, and then sectioning knee joints. Specimens were
fixed for 24 hours and demineralized in phosphate-buffered
saline-0.5 M EDTA for 10 days. Knee joints were embedded in
paraffin and sections were cut and stained with hematoxylin
and eosin (H&E) for evaluation of inflammation. For analysis of
damage to cartilage, knee sections were stained with Toluid-
ine blue, Safranin-O and Masson trichrome following standard
methodology. The sections were scored by two blinded
Table 1
Primer sets used for quantitative PCR study
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observers. Synovial inflammation was scored on a scale of 0
to 3: 0, no inflammation; 1, slight thickening of synovial cell
layer and/or some inflammatory cells in the sublining; 2, thick-
ening of synovial lining, infiltration of the sublining; and 3, pan-
nus formation.
Exudate was scored according to the following scale: 0, no
detectable neutrophil infiltration in the synovial space; 1, mild
infiltration; 2, moderate infiltration; and 3, severe infiltration.
Cartilage damage was evaluated following a scale of 0 to 3: 0,
normal cartilage; 1, cartilage surface irregularities and loss of
metachromasia adjacent to superficial chondrocytes; 2, fibril-
lation of cartilage and formation of some chondrocyte clusters,
with minor loss of surface cartilage; and 3, gross cartilage
abnormalities, including loss of superficial cartilage, extension
of fissures close to subchondral bone, and a large number of
chondrocyte clusters.
Fibroblast like synoviocytes
Fibroblast-like synoviocytes (FLSs) were isolated from parp-
1+/+, parp-1+/o and parp-1o/o mice. Synovial tissue was minced
and incubated with 1 mg/ml collagenase in serum-free DMEM
(Gibco, Invitrogen, Barcelona, Spain) for 3 hours at 37°C.
After digestion, FLSs were filtered trough a nylon cell strainer
(BD Falcon, Franklin Lakes, NJ, USA), washed extensively, and
cultured in DMEM supplemented with 10% v/v FCS (Gibco,
Invitrogen), penicillin, streptomycin, and L-glutamine (Sigma,
St Louis, MO, USA) in a humidified 5% CO2 atmosphere. After
overnight culture, non-adherent cells were removed, and
adherent cells were cultured in DMEM supplemented with
10% v/v FCS.
Western blot analysis
Total proteins (20 µg) were separated by 10% SDS-PAGE,
transferred to a PVDF membrane (Hybond-P, Amersham Bio-
sciences, Buckinghamshire, UK) and probed with anti-PARP-
1 (VIC-5, kindly provided by G de Murcia, CNRS, Strasbourg,
France) and anti-actin (Sigma) antibodies as previously
described [24]. Bound antibody was revealed with goat anti-
rabbit-horseradish peroxidase (Rockland Immunochemicals
Inc., Gilbertsville, PA, USA) and the blot was developed using
the ECL plus detection system (Amersham Biosciences).
Quantitative reverse transcription-PCR
Total RNA was obtained from joints of parp-1+/+ and parp-1o/o
mice on day 7 following Arthrogen injection, and from joints of
parp-1+/+ and parp-1o/o control mice without arthritis. We used
the RNeasy Kit and RNase-Free DNase Set (Qiagen GmbH,
Hilden, Germany) according to the manufacturer's instruc-
Figure 1
Poly(ADP-ribose) polymerase (PARP)-1 expression in joint tissue Poly(ADP-ribose) polymerase (PARP)-1 expression in joint tissue. (a) Western blot analysis of PARP-1 and actin proteins in fibroblast-like synovio-
cyte extracts of the indicated genotypes; 100 ng of purified PARP-1 was the control. Immunostaining for PARP-1 expression in the knee joint sec-
tions from (b) parp-1+and (d) parp-1o/o mice. Staining for nuclear PARP-1 showed clear immunopositivity on chondrocytes from parp-1+ mice 
(arrows) whereas chondrocytes from parp-1o/o (arrowheads) remained negative. Negative control staining, by omitting the primary antibody, in knee 
joints from (c) parp-1+ and (e) parp-1o/o mice.Arthritis Research & Therapy    Vol 8 No 1    García et al.
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tions. One microgram of total RNA was subjected to cDNA
synthesis using M-MLV reverse transcriptase, random primers
and RNaseOUT recombinant ribonuclease inhibitor (Invitro-
gen). Quantitative real-time PCR was performed in duplicate in
a Chromo-4 real-time thermal cycler (MJ Research, Waltham,
MA, USA), using a LightCycler DNA Master SYBR Green I kit
(Roche Diagnostics, Barcelona, Spain), according to the man-
ufacturers' protocols. The specific primers used in these reac-
tions are listed in Table 1. Relative levels of gene expression
were normalized to the β-actin gene using the comparative Ct
method, where Ct is the cycle at which the amplification is ini-
tially detected. The relative amount of mRNA from the different
genes was calculated using the formula 2-∆∆Ct, where:
∆∆Ct = [Cttarget - Ctβ-actin]WT or KO with arthritis - [Cttarget - Ctβ-actin]WT
or KO controls
For wild-type (WT) and PARP-1 deficient samples without
arthritis, ∆∆Ct equals zero and 20 equals one. For wild-type
and knockout (KO) samples with arthritis, the value of 2-∆∆Ct
indicates the fold change in gene expression relative to the
wild-type and knockout controls, respectively. Melting curves
and agarose gel electrophoresis established the purity of the
amplified band.
Determination of cytokines in mice arthritic knees
Knee joints were obtained, frozen in liquid nitrogen and
homogenized in 0.5 ml ice-cold 20 mM Hepes buffer supple-
mented with 1 mM dithiothreitol, 0.1% v/v Triton and a pro-
tease inhibitor cocktail. After incubation for 30 minutes at 4°C,
the homogenate was centrifuged for 10 minutes at 10,000 ×
g. Protein concentration was measured in supernatants by the
Bradford method and a volume containing 100 µg of proteins
was subjected to ELISA for IL-1β, TNF-α, IL-6 and MCP-1
(OptEIA ELISA Sets, BD Pharmingen), according to the man-
ufacture's instructions.
Statistical analysis
Differences between experimental groups were assessed by
ANCOVA, MANCOVA and Mann-Whitney U test. p values
<0.05 were considered significant.
Figure 2
Reduced severity of arthritis in poly(ADP-ribose) polymerase (PARP)-1 deficient mice and PARP-1 sufficient mice following collagen antibody- induced arthritis induction Reduced severity of arthritis in poly(ADP-ribose) polymerase (PARP)-1 deficient mice and PARP-1 sufficient mice following collagen antibody-
induced arthritis induction. (a) Representative pictures of arthritis in the parp-1+ (left panels) and parp-1o/o (right panels) mice. (b) Clinical score was 
measured in 18 parp-1+/+, 8 parp-1+/o and 19 parp-1o/o mice from day 5 to day 12 after injection. Values are expressed as mean ± standard error of 
the mean; p = 0.03, parp-1+/+ and parp-1+/o versus parp-1o/o mice, by ANCOVA test.Available online http://arthritis-research.com/content/8/1/R14
Page 5 of 9
(page number not for citation purposes)
Results
PARP-1 protein expression in joint tissue
Although PARP-1 is found in the majority of the nucleated cells
of the body, its expression in joint tissue has never been stud-
ied. Here, we have analyzed PARP-1 protein expression by
western blot in isolated FLSs from wild-type (parp-1+/+) mice,
mice lacking PARP-1 (parp-1o/o), and parp-1  heterozygous
mice (parp-1+/o). PARP-1 was highly expressed in FLSs from
PARP-1 wild-type mice, moderately expressed in parp-1+/o
and was absent in parp-1o/o mice (Figure 1a). Comparable
results were obtained in the immunohistochemical analysis of
joint sections from parp-1+/+ and  parp-1o/o mice with anti-
PARP-1 antibody (Figure 1b, d).
Reduced severity of arthritis in mice lacking PARP-1
To investigate the contribution of PARP-1 to experimental
arthritis, we induced CAIA in control and PARP-1 deficient
mice (Figure 2a). In eight separate experiments, male and
female parp-1+/+ (n = 18), parp-1+/o (n = 8) and parp-1o/o (n =
19) mice were injected with Arthrogen and lipopolysaccharide
and monitored for signs of arthritis. Evolution of arthritis was
evaluated by two blinded observers on a 0 to 4 scale, as
described in Materials and methods.
There was no difference in incidence or clinical course of
arthritis in parp-1o/o animals compared with parp-1+ control
mice. The incidence of disease was 100% in control mice and
94.7% in parp-1o/o mice. In both groups, arthritis developed
rapidly, the signs of disease appearing as soon as three to five
days after the injection of antibody, and reached maximum
severity around day seven to nine. PARP-1 deficient mice con-
sistently displayed significantly lower severity of arthritis than
parp-1+control mice (p = 0.03 by repeated measures 1-way
ANCOVA test) all through the follow-up (Figure 2b).
These results suggest that PARP-1 has a role in the pathogen-
esis of this arthritis model.
As parp-1+/+ and parp-1+/o control mice had similar clinical
phenotypes, for further analysis, they were pooled together
and considered as parp-1+.
Reduced histological features of joint inflammation and 
cartilage damage in PARP-1 deficient mice
To quantify joint involvement, we assessed synovial inflamma-
tion in H&E stained sections of knee joints. Joints were taken
from 14 parp-1o/o and 13 parp-1+ mice on days 5, 7 and 12,
and histological sections were scored by two blinded observ-
ers on a 0 to 3 scale, corresponding to the degree of thicken-
ing of the synovial lining, sublining infiltration and pannus
formation. On this scale, we observed a clear trend to a lower
synovial inflammation score in parp-1o/o mice compared to
parp-1+mice (Figures 3 and 4), although the difference was
not significant (p = 0.058, by 1-way MANCOVA fixed effects
test).
Joint sections were also stained with Toluidine blue, Safranin-
O and Masson trichrome to evaluate cartilage damage. The
results also showed a trend to less damage in parp-1o/o mice
(Figures 3 and 5), although, again, the difference did not reach
statistical significance (p = 0.053, by 1-way MANCOVA fixed
effects test). When we considered synovial inflammation and
cartilage damage jointly as two facets of the arthritic lesions,
the difference between parp-1o/o and parp-1+ mice was signif-
icant (p = 0.03).
Thus, PARP-1 protein appeared to be involved in the patho-
genesis of the CAIA model, both in synovial inflammation and
Figure 3
Milder synovial inflammation and cartilage damage in poly(ADP-ribose) polymerase (PARP)-1 deficient mice than in control mice Milder synovial inflammation and cartilage damage in poly(ADP-ribose) polymerase (PARP)-1 deficient mice than in control mice. Histopathological 
scoring of (a) synovial inflammation and (b) cartilage damage of knee joint sections of parp-1+mice and parp-1o/o mice at day 5 and 12 after induc-
tion of collagen antibody-induced arthritis. Values are expressed as mean ± standard error of the mean; p = 0.03, parp-1+ versus parp-1o/o mice by 
combined analysis of (a) and (b) (MANCOVA test).Arthritis Research & Therapy    Vol 8 No 1    García et al.
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cartilage damage, although it did not seem to have a pivotal
role.
It has been previously described that, in several rodent models
of inflammation, PARP-1 activation is involved in neutrophil
recruitment [25]. Neutrophils have been implicated in arthritis
disease; specifically, extensive neutrophil exudate is displayed
in CAIA model [23] and neutrophils release elastase and pro-
teases, which degrade proteoglycans [4]. It remains possible
that the decreased severity of arthritis observed in PARP-1
deficient mice was associated with reduced neutrophil exu-
date in joints from these mice. To evaluate this possibility, we
assessed, at five and seven days, the exudate score on a 0 to
3 scale in H&E stained sections of knee joints. Exudate
appeared slightly lower in parp-1o/o compared to parp-1+ mice,
although the difference was not significant (p = 0.12, by 1-way
MANCOVA fixed effects test) (Figure 6). Thus, lack of PARP-
1 does not impair neutrophil exudation in this arthritis model.
Expression levels of inflammatory mediators in arthritic 
joints from PARP-1 deficient and sufficient mice
To explore the possible mechanisms underlying the reduced
arthritis observed in PARP-1 knockout mice compared to
control mice, we studied, by quantitative real-time PCR, mRNA
levels of IL-1β, IL-6, TNF-α, MCP-1, small inducible cytokine
A5 (Cc15; RANTES), inducible nitric oxide synthase (iNOS)
and cyclooxygenase (COX)-2 in arthritic joints at day seven
after Arthrogen injection. The fold change in mRNA of arthritic
versus non-arthritic parp-1o/o and parp-1+ mice is shown in Fig-
ure 7. All the inflammatory mediators were detected in both
groups of mice and, interestingly, IL-1β and MCP-1 mRNA
were significantly less induced in arthritic parp-1o/o compared
to arthritic parp-1+ mice. IL-6 mRNA showed a trend towards
lower induction in parp-1o/o compared to parp-1+ arthritic mice
(p = 0.1, by Mann-Whitney U test). However, mRNA expres-
sion of TNF-α and Ccl5 were induced to a similar extend in
Figure 4
Representative hematoxylin-eosin stained sections of knee joints in  mice with collagen antibody-induced arthritis (CAIA) Representative hematoxylin-eosin stained sections of knee joints in 
mice with collagen antibody-induced arthritis (CAIA). Severe inflamma-
tion, pannus formation and associated cartilage destruction were 
observed in sections stained with hematoxylin-eosin from parp-1+ mice 
at (a) day 5 and (b) day 12 after CAIA induction compared to parp-1o/o 
mice at (c) day 5 and (d) day 12.
Figure 5
Representative sections stained with Safranin O in mice with collagen  antibody-induced arthritis (CAIA) Representative sections stained with Safranin O in mice with collagen 
antibody-induced arthritis (CAIA). More severe loss of proteoglycans, 
indicated by destained cartilage layers, were observed in sections from 
parp-1+ mice at (a) day 5 and (b) day 12 after CAIA induction com-
pared with knockout mice at (c) day 5 and (d) day 12.
Figure 6
Comparable exudate scores in the arthritic joints of parp-1+ and parp- 1o/o mice Comparable exudate scores in the arthritic joints of parp-1+ and parp-
1o/o mice. Exudate score was evaluated in knee sections stained with 
hematoxylin-eosin from parp-1+and parp-1o/o mice at day 5 and 7 after 
induction of collagen antibody-induced arthritis. Values represent the 
mean ± standard error of the mean. Differences between parp-1+and 
parp-1o/o mice were not statistically significant (p = 0.12 by 1-way 
MANCOVA test).Available online http://arthritis-research.com/content/8/1/R14
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both groups of arthritic mice (p = 0.9 and p = 0.7, respectively,
by Mann-Whitney U test). Transcription of genes encoding
iNOS and COX-2, which are involved in the synthesis of nitric
oxide and prostaglandin E2, respectively, were induced to lev-
els that were not significantly different in PARP-1 deficient and
sufficient arthritic mice. However, a tendency towards lower
induction in the parp-1o/o mice was noted.
To confirm these findings, we next determined the levels of IL-
1β, IL-6, TNF-α and MCP-1 proteins in joint tissues. IL-1β and
MCP-1 were significantly reduced in joints from arthritic parp-
1o/o compared to arthritic parp-1+ mice (Figure 8); however,
there was no difference in the production of TNF-α and IL-6 in
both groups of mice (p = 0.4 and p = 0.3, respectively, by
Mann-Whitney U test). These results are consistent with those
obtained for the mRNA analysis.
Discussion
Previous studies using genetically engineered animals and
pharmacological inhibitors have implicated PARP-1 in the
pathogenesis of several inflammatory processes [13-16]. In
the present report, we have investigated the impact of
selective PARP-1 suppression in the CAIA model and found
that absence of PARP-1 protein reduces the severity of dis-
ease, likely by the impairment of IL-1β and MCP-1 transcrip-
tion in joint tissues. In the arthritis model used, disease
develops in most mice strains, avoiding multiple breeding into
arthritis susceptible strains. Using a suitable antibody dose,
arthritis incidence rises to 100% in control animals and the
clinical severity and histopathology are similar to collagen-
induced arthritis and human RA. Given the involvement of
PARP-1 in inflammation, we considered that it could have a
role in the effector phase of arthritis; the CAIA model specifi-
cally reflects this phase.
PARP-1 deficient mice had decreased severity in clinical and
histological arthritis, although the incidence of disease was
similar in control and deficient mice. This is in line with its
described involvement in other inflammatory diseases, but
with milder effect in the case of arthritis.
PARP-1 belongs to a large family of 18 proteins, encoded by
different genes and displaying a conserved catalytic domain
(for reviews, see [26,27]). PARP-1 catalyzes 80% of cellular
poly(ADPribosyl)ation and the other PARP family members,
PARP-2, PARP-3, PARP-4 and Tankyrases (PARP-5 a and b),
all identified in the last few years, account for the remaining
20%. Therefore, it is possible that when PARP-1 is absent
from development, other PARP family members with
poly(ADPribosyl)ation activity could compensate for its
absence. To evaluate this possibility, we treated parp-1o/o and
parp-1+  mice with 3,4-dihydro-5- [4-(1-piperidinyl)butoxy]-
1(2H)-isoquinolinone (DPQ), one of the new potent PARP
inhibitors developed. After treatment, we found similar protec-
Figure 7
Reduced IL-1β and monocyte chemotactic protein (MCP)-1 mRNA levels in mice lacking poly(ADP-ribose) polymerase (PARP)-1 Reduced IL-1β and monocyte chemotactic protein (MCP)-1 mRNA levels in mice lacking poly(ADP-ribose) polymerase (PARP)-1. IL-1β, MCP-1, 
inducible nitric oxide synthase (iNOS), cyclooxygenase (COX)-2, tumor necrosis factor (TNF)-α, IL-6 and small inducible cytokine A5 (Ccl5) mRNA 
levels were measured by quantitative real-time PCR in arthritic joints of parp-1+ and parp-1o/o mice at day 7 after induction of collagen antibody-
induced arthritis. Values are expressed as mean ± standard error of the mean of six to nine mice per group. Differences between parp-1+ and parp-
1o/o mice were statistically significant for IL-1β (asterisk indicates p = 0.005) and MCP-1 (asterisk indicates p = 0.004) by Mann-Whitney U test.Arthritis Research & Therapy    Vol 8 No 1    García et al.
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tion to that observed in mice lacking the parp-1 gene (data not
shown), suggesting that PARP-1 is the member of the PARP
proteins involved in arthritis inflammation.
Our results contrast with the significantly reduced incidence
and severity of collagen induced arthritis in mice treated with
INH2BP, a PARP inhibitor, reported by Szabo and colleagues
[28]. It is possible that INH2BP has effects other than the inhi-
bition of PARP function, because we did not observe such a
strong effect with knockout mice, nor with the DPQ inhibitor.
Nevertheless, this discordance could also be attributed to
either differences in the arthritis model or differences in the
inhibitors. In fact, it has been recently shown that another
PARP inhibitor, PJ34, reduces the severity rather than inci-
dence of collagen induced arthritis [16].
IL-1β is one of the major cytokines in arthritis driving inflamma-
tion and joint destruction [2,4,7]. It has been reported that sys-
temic administration of IL-1 accelerates and exacerbates the
development of murine collagen induced arthritis [29], while
IL-1 receptor antagonist-deficient mice (BALB/c background)
develop chronic polyarthropathy resembling RA [30]. MCP-1
is a potent chemoattractant for monocytes. It seems to be
involved in RA pathogenesis because it has been detected in
patient sera and found at increased levels in FLSs from RA
patients [31-33]. It has been recently reported that MCP-1
induces FLS proliferation, which is pivotal in pannus formation,
and increases metalloproteinase production mediated by IL-
1β [34].
Thus, the strong reduction in IL-1β and MCP-1 production
o b s e r v e d  i n  P A R P - 1  d e f i c i ent mice may account for the
reduced severity of arthritis, though signals of a more wide-
spread effect are reflected in the tendency towards the
decreased expression of other inflammatory mediators, such
as IL-6, iNOS and COX-2.
In contrast to what has been described in the shock endotoxic
model [13,16], we did not find impaired TNF-α production in
mice lacking PARP-1. This could indicate that the require-
ments of PARP-1 for transcription of inflammatory genes
depend on the tissue and the nature of the inflammatory stim-
ulus. In fact, studies with a PARP inhibitor have shown an
inhibitory or neutral effect on IL-1β levels depending on the
model of inflammation [16].
Conclusion
Overall, our results indicate that PARP-1 plays a role in arthritis
progression, probably through impaired IL-1β and MCP-1 pro-
duction in joints. Although further investigations are required
to evaluate PARP-1 involvement in human RA, this enzyme
might be considered as a new target for experimental
treatment.
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